[1] TAGLIALEGNA A. Helping C. difficile to thrive[J]. Nat Rev Microbiol, 2023, 21(2):65.
[2] CHEN J, LI Y, WANG S, et al. Targeting Clostridioides difficile: new uses for old drugs[J]. Drug Discov Today, 2022, 27(7):1862-1873. doi:  10.1016/j.drudis.2022.03.021
[3] LIM S C, KNIGHT D R, RILEY T V. Clostridium difficile and one health[J]. Clin Microbiol Infect, 2020, 26(7):857-863. doi:  10.1016/j.cmi.2019.10.023
[4] LILIENKAMPF A, MAO J, WAN B, et al. Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis[J]. J Med Chem, 2009, 52(7): 2109-2118.
[5] SILVA J, BATTS D H, FEKETY R, et al. Treatment of Clostridium difficile colitis and diarrhea with vancomycin[J]. Am J Med, 1981, 71(5):815-822.
[6] NASVELD P, KITCHENER S. Treatment of acute vivax malaria with tafenoquine[J]. Trans R Soc Trop Med Hyg, 2005, 99(1):2-5. doi:  10.1016/j.trstmh.2004.01.013
[7] LEATHAM P A, BIRD H A, WRIGHT V, et al. A double blind study of antrafenine, naproxen and placebo in osteoarthrosis[J]. Eur J Rheumatol Inflamm, 1983, 6(2):209-211.
[8] LAM K H, GAMBARI R, YUEN M C W, et al. The preparation of 2, 6-disubstituted pyridinyl phosphine oxides as novel anti-cancer agents[J]. Bioorg Med Chem Lett, 2009, 19(8):2266-2269. doi:  10.1016/j.bmcl.2009.02.091
[9] MAHAMOUD A, CHEVALIER J, DAVIN-REGLI A, et al. Quinoline derivatives as promising inhibitors of antibiotic efflux pump in multidrug resistant Enterobacter aerogenes isolates[J]. Curr Drug Targets, 2006, 7(7):843-847. doi:  10.2174/138945006777709557
[10] MUSIOL R, TABAK D, NIEDBALA H, et al. Investigating biological activity spectrum for novel quinoline analogues 2: Hydroxyquinolinecarboxamides with photosynthesis-inhibiting activity[J]. Bioorg Med Chem, 2008, 16(8):4490-4499. doi:  10.1016/j.bmc.2008.02.065
[11] PALIT P, PAIRA P, HAZRA A, et al. Phase transfer catalyzed synthesis of bis-quinolines: Antileishmanial activity in experimental visceral leishmaniasis and in vitro antibacterial evaluation[J]. Eur J Med Chem, 2009, 44(2):845-853. doi:  10.1016/j.ejmech.2008.04.014
[12] MUSIOL R, JAMPILEK J, KRALOVA K, et al. Investigating biological activity spectrum for novel quinoline analogues[J]. Bioorg Med Chem, 2007, 15(3):1280-1288. doi:  10.1016/j.bmc.2006.11.020
[13] BARNHAM K J, GAUTIER E C, KOK G B, et al. 8-hydroxy quinoline derivatives. WO2004007461 A1[P]. 2004.
[14] LAM K H, GAMBARI R, LEE K K H, et al. Preparation of 8-hydroxyquinoline derivatives as potential antibiotics against Staphylococcus aureus[J]. Bioorg Med Chem Lett, 2014, 24(1):367-370. doi:  10.1016/j.bmcl.2013.10.072
[15] FENG L, MADDOX M M, ALAM M Z, et al. Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives[J]. J Med Chem, 2014, 57(20):8398-8420. doi:  10.1021/jm500853v
[16] ZHANG L, MEGGERS E. An extremely stable and orthogonal DNA base pair with a simplified three-carbon backbone[J]. J Am Chem Soc, 2005, 127(1):74-75. doi:  10.1021/ja043904j
[17] KOHO K T. Preparation of carbostyryl derivatives as phosphodiesterase (PDE) inhibitors for treatment of heart failure, hypertension, Crohn’s disease, etc. JP2009040711[P]. 2009.